IL164652A0 - Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside - Google Patents
Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycosideInfo
- Publication number
- IL164652A0 IL164652A0 IL16465204A IL16465204A IL164652A0 IL 164652 A0 IL164652 A0 IL 164652A0 IL 16465204 A IL16465204 A IL 16465204A IL 16465204 A IL16465204 A IL 16465204A IL 164652 A0 IL164652 A0 IL 164652A0
- Authority
- IL
- Israel
- Prior art keywords
- blocker
- administration
- calcium channel
- cardiac glycoside
- adenosine agonist
- Prior art date
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract 2
- 206010003119 arrhythmia Diseases 0.000 title abstract 2
- 230000006793 arrhythmia Effects 0.000 title abstract 2
- 239000002876 beta blocker Substances 0.000 title abstract 2
- 229940097320 beta blocking agent Drugs 0.000 title abstract 2
- 239000000480 calcium channel blocker Substances 0.000 title abstract 2
- 229940097217 cardiac glycoside Drugs 0.000 title abstract 2
- 239000002368 cardiac glycoside Substances 0.000 title abstract 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 title abstract 2
- 239000003379 purinergic P1 receptor agonist Substances 0.000 title abstract 2
- 229930002534 steroid glycoside Natural products 0.000 title abstract 2
- 101150007969 ADORA1 gene Proteins 0.000 abstract 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376602P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/012043 WO2003088978A1 (en) | 2002-04-18 | 2003-04-18 | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164652A0 true IL164652A0 (en) | 2005-12-18 |
Family
ID=29251078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16465204A IL164652A0 (en) | 2002-04-18 | 2004-10-18 | Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7005425B2 (https=) |
| EP (1) | EP1494685B1 (https=) |
| JP (1) | JP2005530736A (https=) |
| KR (1) | KR20040106354A (https=) |
| CN (2) | CN1646142A (https=) |
| AT (1) | ATE418991T1 (https=) |
| AU (1) | AU2003235466C1 (https=) |
| CA (1) | CA2482928A1 (https=) |
| DE (1) | DE60325572D1 (https=) |
| ES (1) | ES2318129T3 (https=) |
| IL (1) | IL164652A0 (https=) |
| MX (1) | MXPA04010285A (https=) |
| NO (1) | NO20045005L (https=) |
| NZ (1) | NZ536001A (https=) |
| RU (1) | RU2332220C2 (https=) |
| WO (1) | WO2003088978A1 (https=) |
| ZA (1) | ZA200408411B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514515A (en) | 1999-03-23 | 2003-11-28 | Global Cardiac Solutions Pty L | Organ arrest, protection and preservation using a potassium channel operator and/or adenosine receptor and a local anaesthetic |
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
| US7157440B2 (en) * | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7713946B2 (en) * | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| ATE418991T1 (de) * | 2002-04-18 | 2009-01-15 | Cv Therapeutics Inc | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| GB2436255B (en) * | 2002-12-23 | 2007-11-28 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery |
| EP1768991A1 (en) * | 2004-07-12 | 2007-04-04 | Cv Therapeutics, Inc. | Process for the preparation of a1-adenosine receptor agonists |
| US20060019954A1 (en) * | 2004-07-20 | 2006-01-26 | Cedars-Sinai Medical Center | Method for reducing the likelihood of the occurrence of cardiac arrhythmias |
| US7300923B2 (en) * | 2004-08-30 | 2007-11-27 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| EP1802775B1 (en) | 2004-09-14 | 2010-05-26 | The Regents of the University of Colorado | Method for treatment with bucindolol based on genetic targeting |
| US7822474B2 (en) * | 2005-11-30 | 2010-10-26 | Cedars-Sinai Medical Center | Methods for the prediction of arrhythmias and prevention of sudden cardiac death |
| WO2007092372A1 (en) | 2006-02-03 | 2007-08-16 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| AU2006345361B2 (en) | 2006-05-29 | 2014-04-10 | Hibernation Therapeutics, A Kf Llc | Improved tissue maintenance |
| CA2692256C (en) | 2006-07-25 | 2017-01-10 | Hibernation Therapeutics Limited | Trauma therapy |
| EP2173353B1 (en) | 2007-03-02 | 2015-05-06 | Hibernation Therapeutics, a KF LLC | Composition including Adenosine and Lignocaine |
| HRP20121045T1 (hr) | 2007-12-21 | 2013-01-31 | Aop Orphan Pharmaceuticals Ag | Farmaceutska smjesa za parenteralnu primjenu antagonista beta-adrenoreceptora ultrakratkog djelovanja |
| MX2011003168A (es) * | 2008-09-29 | 2011-05-19 | Gilead Sciences Inc | Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples. |
| GB0903299D0 (en) | 2009-02-26 | 2009-04-08 | Guys And St Thomas Nhs Foundat | Composition and methods |
| CA2835771C (en) * | 2009-03-18 | 2017-01-24 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| US20110039799A1 (en) | 2009-08-14 | 2011-02-17 | Gilead Palo Alto, Inc. | A1 adenosine receptor agonist polymorphs |
| LT2523669T (lt) | 2010-01-11 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Akispūdžio mažinimo būdas, derinys ir rinkinys |
| US8455457B2 (en) * | 2010-03-19 | 2013-06-04 | Inotek Pharmaceuticals Corporation | Combination compositions for reducing intraocular pressure |
| PH12012501906A1 (en) | 2010-03-26 | 2013-01-14 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
| PT2807178T (pt) | 2012-01-26 | 2017-08-08 | Inotek Pharmaceuticals Corp | Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação |
| NZ630759A (en) | 2013-03-15 | 2017-07-28 | Inotek Pharmaceuticals Corp | Ophthalmic formulations comprising an a1 agonist |
| BR112016000809A2 (pt) | 2013-07-17 | 2017-08-22 | Hibernation Therapeuitics A Kf Llc | Método para tratar infecção, sepsia e lesão |
| AU2014361813A1 (en) * | 2013-12-13 | 2016-07-28 | Ralph ANKENMAN | Compositions and methods for treating dysregulated systems |
| CN114847965A (zh) | 2016-02-01 | 2022-08-05 | 英凯达治疗公司 | 电子监测联合吸入药理学疗法管理心律失常 |
| CN106370754B (zh) * | 2016-11-07 | 2019-03-08 | 西安科技大学 | 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法 |
| CA3060702A1 (en) | 2017-05-10 | 2018-11-15 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| ES3040411T3 (en) | 2018-03-22 | 2025-10-30 | Incarda Therapeutics Inc | A novel method to slow ventricular rate |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| KR102891439B1 (ko) | 2019-08-01 | 2025-11-25 | 인카다 테라퓨틱스, 인크. | 항부정맥 제제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108363A (en) * | 1988-02-19 | 1992-04-28 | Gensia Pharmaceuticals, Inc. | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist |
| US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| EP0907644A4 (en) * | 1996-06-28 | 2003-02-05 | Merck & Co Inc | PHARMACEUTICAL PREPARATION |
| US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| JP2001509808A (ja) * | 1997-01-31 | 2001-07-24 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 多機能性カルシウム／カルモジュリン−依存性プロテインキナーゼの阻害による不整脈の処置 |
| CO5180581A1 (es) * | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| US6576620B2 (en) * | 1999-12-03 | 2003-06-10 | Cv Therapeutics, Inc. | Method of identifying partial adenosine A1 receptor agonists |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6537974B2 (en) * | 2000-09-08 | 2003-03-25 | Cv Therapeutics, Inc. | Method of treating arrhythmias |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| ATE418991T1 (de) * | 2002-04-18 | 2009-01-15 | Cv Therapeutics Inc | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker |
-
2003
- 2003-04-18 AT AT03724098T patent/ATE418991T1/de not_active IP Right Cessation
- 2003-04-18 CN CNA038086999A patent/CN1646142A/zh active Pending
- 2003-04-18 DE DE60325572T patent/DE60325572D1/de not_active Expired - Lifetime
- 2003-04-18 RU RU2004130826/14A patent/RU2332220C2/ru not_active IP Right Cessation
- 2003-04-18 EP EP03724098A patent/EP1494685B1/en not_active Expired - Lifetime
- 2003-04-18 CN CNA2008101711378A patent/CN101385738A/zh active Pending
- 2003-04-18 AU AU2003235466A patent/AU2003235466C1/en not_active Ceased
- 2003-04-18 MX MXPA04010285A patent/MXPA04010285A/es active IP Right Grant
- 2003-04-18 KR KR10-2004-7016764A patent/KR20040106354A/ko not_active Abandoned
- 2003-04-18 US US10/418,654 patent/US7005425B2/en not_active Expired - Fee Related
- 2003-04-18 JP JP2003585730A patent/JP2005530736A/ja active Pending
- 2003-04-18 NZ NZ536001A patent/NZ536001A/en not_active IP Right Cessation
- 2003-04-18 CA CA002482928A patent/CA2482928A1/en not_active Abandoned
- 2003-04-18 ES ES03724098T patent/ES2318129T3/es not_active Expired - Lifetime
- 2003-04-18 WO PCT/US2003/012043 patent/WO2003088978A1/en not_active Ceased
-
2004
- 2004-10-18 ZA ZA200408411A patent/ZA200408411B/en unknown
- 2004-10-18 IL IL16465204A patent/IL164652A0/xx unknown
- 2004-11-17 NO NO20045005A patent/NO20045005L/no not_active Application Discontinuation
-
2005
- 2005-10-28 US US11/262,025 patent/US7479485B2/en not_active Expired - Fee Related
-
2009
- 2009-01-09 US US12/351,731 patent/US20090118221A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2318129T3 (es) | 2009-05-01 |
| US20030216349A1 (en) | 2003-11-20 |
| MXPA04010285A (es) | 2005-02-03 |
| JP2005530736A (ja) | 2005-10-13 |
| NZ536001A (en) | 2006-05-26 |
| US20090118221A1 (en) | 2009-05-07 |
| US7479485B2 (en) | 2009-01-20 |
| DE60325572D1 (de) | 2009-02-12 |
| AU2003235466A1 (en) | 2003-11-03 |
| RU2332220C2 (ru) | 2008-08-27 |
| NO20045005L (no) | 2004-11-17 |
| CN101385738A (zh) | 2009-03-18 |
| ATE418991T1 (de) | 2009-01-15 |
| CA2482928A1 (en) | 2003-10-30 |
| US20060052333A1 (en) | 2006-03-09 |
| US7005425B2 (en) | 2006-02-28 |
| EP1494685A1 (en) | 2005-01-12 |
| ZA200408411B (en) | 2006-02-22 |
| RU2004130826A (ru) | 2005-05-10 |
| AU2003235466C1 (en) | 2008-03-20 |
| WO2003088978A1 (en) | 2003-10-30 |
| KR20040106354A (ko) | 2004-12-17 |
| EP1494685B1 (en) | 2008-12-31 |
| CN1646142A (zh) | 2005-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL164652A0 (en) | Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside | |
| WO2004043377A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| WO2003097052A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| ES2158778A1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| CA2146973A1 (en) | Uses of tgf-.beta. receptor fragment as a therapeutic agent | |
| AR051446A1 (es) | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) | |
| WO2004006859A3 (en) | Platinum compound | |
| MY129445A (en) | Compositions for treating inflammatory response | |
| AU2001292579A1 (en) | Methods and compounds for treating proliferative diseases | |
| WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
| ES2088771A1 (es) | Metodo para mejorar la acividad reproductora en verracos utilizando alimento para los verracos reproductores. | |
| WO2001045684A3 (en) | Formulations of adenosine a1 agonists | |
| AU2002342808A1 (en) | Extract with anti-tumor and anti-poisonous activity | |
| MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
| PL376346A1 (en) | Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration | |
| GB9924941D0 (en) | Treatment of dyskinesia | |
| MY133682A (en) | Substituted pyrroles | |
| AU4937499A (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
| AU3360000A (en) | Use of 4-amino pyridine for treatment of peripheral neuropathies | |
| ZA988009B (en) | Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. | |
| AU9259101A (en) | Purine ribosides as antiarrhythmics | |
| EP0904094A4 (en) | TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN | |
| SI1196172T1 (sl) | (S,S)-reboksetin za zdravljenje kronicne bolecine | |
| WO2005094282B1 (en) | Combination therapy comprising cloretazinetm |